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Objective:We sought to summarize the preliminary clinical experience of minimally invasive transthoracic device
closure of perimembranous ventricular septal defects with a new delivery system without cardiopulmonary bypass.
Methods: Twenty-one patients aged 11 months to 12 years (median age, 3.6 years) with isolated perimembranous
ventricular septal defects underwent minimally invasive device closure with an inferior sternotomy of 3 to 5 cm
under transesophageal echocardiographic guidance. A single per–right ventricular U-like suture was established,
and a new delivery system was introduced, aided by a 16-gauge trocar, including a guidewire, proper sheath, and
loading sheath. The proper size of devices was determined by means of transesophageal echocardiographic
analysis, and then the device was released under real-time transesophageal echocardiographic monitoring if no sig-
nificant aortic regurgitation, abnormal atrioventricular valvular motion, or residual interventricular shunt appeared.
Results: All of the defects were successfully closed. No residual shunt, noticeable aortic or tricuspid regurgita-
tion, or significant arrhythmias appeared during more than 5 months of follow-up.
Conclusion: Minimally invasive transthoracic device closure of perimembranous ventricular septal defects with
a new delivery system without cardiopulmonary bypass is feasible and safe under transesophageal echocardio-
graphic guidance. However, it is necessary to evaluate the intermediate and long-term results.
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Perimembranous ventricular septal defects (PMVSDs) are
among the most common congenital cardiac malformations.1,2
Closure is routinely performed with cardiac surgical repair
aided by cardiopulmonary bypass (CPB), with excellent re-
sults.2-4 CPB and sternotomy are important factors that could
lead to increased postoperative morbidity, prolonged hospital
stay, and possible late neurocognitive impairment.5 The long-
term effects of CPB remain elusive, and its effects are more
pronounced in infants than in patients of older age.6
Despite improvements in device closure of PMVSDs, which
was introduced in the late 1980s,7-10 transcatheterization
intervention for PMVSDs is still associated with long-term
morbidity and mortality. In particular, the unascertained poten-
tial injury from exposure to x-rays is not negligible for children
with ventricular septal defects (VSDs).
We describe a new technique to close PMVSDs in which
the defects were closed under transesophageal echocardio-
graphic (TEE) guidance without CPB.
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Patients
Twenty-one continuous patients with PMVSDs underwent transthoracic
minimally invasive device closure without CPB between March and April
2007 aided by a newly designed delivery system. Among these, 13 male
children were included (age range, 11 months to 12 years; median age,
3.6 years; weight 15.8  6.4 kg). All of the children tended to be affected
by respiratory infection. Systolic murmurs of grade 2 to 3 could be heard in
the third intercostal space, with intense pulmonary second heart sounds. As
determined with TEE analysis, the dimensions of the PMVSDs were 3 to 12
mm, with enlarged left atria and ventricles. Mild-to-moderate pulmonary
hypertension was indicated in 7 patients. The ridges of 2 PMVSDs were
adjoined to the aortic valve. X-ray films indicated increased pulmonary
blood or prominent congestion, and cardiac profiles extended left inferiorly.
Electrocardiograph analysis indicated leftward electrical bore sight in 12
patients.
Devices and Delivery System
The entire delivery system consists of a trocar, guidewire, dilator and de-
livery sheath, and a loading sheath (Figure 1) made of polyethylene and
acrylonitrile butadiene styrene and disinfected with ethylene oxide. Oc-
cluder devices were supplied by Shanghai Co Ltd of Xingzhuangjiyi Alloy
Material (no. 20043770007).
Procedure
The chest was opened through an inferior median sternotomy of 3 to
5 cm (Figure 2). The pericardium was cradled. A U-like stitch of 4-0 or
5-0 Prolene sutures (Ethicon, Somerville, NJ) was placed on the free wall
of the right ventricle. TEE analysis was performed to measure the exact
size and location of the PMVSDs. Furthermore, the integrity of the aortic
valve was evaluated. A modified short angiocatheter was passed into the
right ventricle through the free wall, and then the needle was removed
(Figure 3). A 0.035-inch floppy wire was advanced through the angiocath-
eter and aimed toward the PMVSDs. The PMVSDs were crossed, and the
wire was advanced through the defect into the left ventricle. The dilator
was removed, and an appropriately sized delivery sheath was advanced
over the wire into the left ventricle. The wire and the dilator were removed,rgery c March 2009




CPB ¼ cardiopulmonary bypass
PMVSD ¼ perimembranous ventricular septal
defect
TEE ¼ transesophageal echocardiography
TTE ¼ transthoracic echocardiography
VSD ¼ ventricular septal defect
and the sheath was allowed to backbleed to ensure there was no air entrap-
ment (Figure 4). The VSD device was immersed in saline and screwed onto
the delivery cable. The device was loaded with the help of a loading sheath.
The loading sheath was introduced into the delivery sheath, and the device
was advanced to the tip of the sheath. The sheath was gently pulled back un-
til the tip was in the left ventricle, just under the aortic valve. Under echo-
cardiographic guidance, the left disc was deployed; the sheath and the
device were pulled back slowly until the left disc approximated the ventric-
ular septum. The device was gently rotated only if the flat part of the disc
was not directly under the aortic valve. The waist and the right disc of the
occluding device were deployed while maintaining fair traction on the de-
livery cable. The position of the device was checked, the motion of the aortic
valve was evaluated for aortic insufficiency, and the device was released by
rotating the delivery cable anticlockwise. The sheath and the delivery cable
were pulled out of the right ventricle, and the U-like suture on the right ven-
tricular free wall was tied. TEE was again performed to evaluate tricuspid
and aortic regurgitation. The pericardium was partially closed, and a chest
tube was placed in the mediastinum. The sternum was closed with special
sternal wires. The chest wall was closed in routine fashion. Transthoracic
echocardiographic (TTE) analysis was used to evaluate the position of
deployed devices, the motion of the aortic and tricuspid valves, and the
residual interventricular shunt (Figure 5).
RESULTS
Intraoperative and Immediate Postoperative
Conditions
The procedure was successful in all patients. There was no
incidence of device embolization or heart block. Nineteen
cases of isolated PMVSDs were successfully occluded with-
FIGURE 1. Delivery system loading with occluder.The Journal of Thoracic and Cout transfusion. TEE analysis revealed no residual shunts,
abnormal valvular motion, or occluder shift (Figure 5). Sym-
metric devices were used in 19 cases, and nonsymmetric
devices were used in 2 patients whose PMVSD ridges were
close to the aortic valve. The diameter of the device waist
ranged from 4 to 13 mm. The whole process took less than
60 minutes, and the deployment of the device was finished
in less than 30 minutes. The children were extubated in the
intensive care unit, except for 3 patients who were extubated
on the operating room table no more than 2 hours after the
operation. The chest tube was removed 1 to 2 days after the
operation. All were extubated and discharged no later than
96 hours. TTE analysis before discharge revealed normal
cardiac function and a fixed and proper position of the device
without affecting the surrounding tissues.
Follow-up
Up to now, all patients have undergone more than 5
months of follow-up. Aspirin was administered by mouth
at approximately 3 to 5 mg $ kg1 $ d1 during the first 3
months after the operation. Patients were asked to revisit
the cardiology unit at least once a month. TTE analysis
showed good systolic and diastolic function, proper posi-
tioning of the deployed devices, harmonious motion of the
aortic and tricuspid valves, and no residual interventricular
shunt. There was also no hematuria after the procedure.
Normal activities were allowed 2 weeks after discharge.
DISCUSSION
Thus far, there remain 2 main interventions for PMVSDs:
the classical cardiac repair with CPB and percutaneous
transluminal device closure. However, there were noticeable
drawbacks for both surgical repair and transcatheterization clo-
sure of PMVSDs. When it comes to traditional surgical inter-
vention, great trauma and systemic inflammatory reactions
from CPB are always routine complications. Dangers from
FIGURE 2. Incision.ardiovascular Surgery c Volume 137, Number 3 557
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DFIGURE 3. U-like right ventricular suture and needle puncture.intraoperative cardiac arrest are also a great threat. In addition,
incision scars not only have an aesthetic effect but also lead to
psychologic depression of affected children. Potential negative
influences from exposure to x-rays have not been totally
avoided for transcatheterization intervention, especially those
in who have not conceived, even though protective lead
garments have been introduced in these procedures. Simulta-
neously, limited by thin peripheral veins and the dimension
of the device, low-birth-weight young infants are not subjected
to this procedure.
Consequently, many have sought to integrate the 2
methods, which is called hybridization, to avoid potential
complications from CPB and x-ray exposure. The point is
that small inferior sternal and perventricular incisions and
TEE monitoring without exposure to x-rays effectively ensure
the safe deployment of the device and also greatly decrease
morbidity from these traditional procedures. Innovation of
the delivery system becomes the core point. In the past 10
years, many physicians in different heart centers, especially
those dealing with congenital heart disease, have attempted
to design and improve the delivery system.11-14
After performing transthoracic minimally invasive device
closure of atrial septal defect secundum,15 we redesigned the
delivery system and succeeded in PMVSD closure. The
most prominent character of this new system is its short
dimension. It can be held in a single hand so that 1 person
can perform the whole procedure. By gently pressing the
free wall of the right ventricle, the best point for puncture
closest to the PMVSD can be ascertained. It is also possible
to adjust the sheath to be parallel to the defect, which
decreases the damage to the myocardial and adjacent tissues.
The whole process can be monitored and guided by means
of TEE. Once a patient is considered not suitable for such
a procedure or the device closure fails, the surgeons can
immediately elongate the incision, completely cut open the
sternum, and convert to traditional surgical repair without
additional incisions or rearranging the operation from the
catheterization laboratory to the operating room, which
ensures the safety of the procedure. More importantly,
such a hybrid intervention is available in almost all types
of VSD, including muscular and perimembranous VSDs,558 The Journal of Thoracic and Cardiovascular Sueven those close to the aortic valve. Intraoperative real-time
TEE guidance is another key point.16 Almost the total pro-
cess is dependent on the guidance of clear TEE pictures,
and therefore experienced echocardiographers are in great
demand. Aided by TEE, dimension of the VSD, adjacent tis-
sue, and valvular structure and motion, especially intraoper-
ative positioning of the delivery system, can be clearly
shown.
Therefore performance of transthoracic minimally inva-
sive device closure could be thought of as a great advance
for PMVSD closure. Prospectively, with further experience
accumulating, more patients with VSDs can benefit from
transthoracic minimally invasive device closure.
References
1. Mitchell SC, Korones SB, Berendes HW. Congenital heart disease I 56,109 births.
Circulation. 1971;43:323-32.
2. Kidd L, Driscoll DJ, Gersony WM, Haves CJ, Keane JF, O’Fallon WM, et al. Sec-
ond natural history study of congenital heart defects: results of treatment of
patients with ventricular septal defects. Circulation. 1993;87(suppl I):138-51.
3. Rudolph AM. Ventricular septal defect. In: Rudolph AM, ed. Congenital diseases
of the heart: clinical-physiological considerations. 2nd ed. Armonk (NY): Futura;
2000. p. 197-244.
4. Backers CL, Winters RC, Zales VR, Takami H, Muster AJ, Benson DW Jr, et al.
The restrictive ventricular septal defect: how small is too small to close? Ann
Thorac Surg. 1993;56:10-4.
5. Rose EA. Off-pump coronary artery bypass surgery. N Engl J Med. 2003;348:
379-80.
6. Kern FH, Hickey PR. The effects of cardiopulmonary bypass on the brain. In:
Jonas RA, ed. Cardiopulmonary bypass in neonates, infants and young children.
1st ed. Boston: Blackwell Science; 1994. p. 263-78.
7. Lock JE, Block PC, McKay RG, Baim DS, Keane JF. Transcatheter closure of
ventricular septal defects. Circulation. 1988;78:361-8.
8. Janorkar S, Goh T, Wilkinson J. Transcatheter closure of ventricular septal defects
using the Rashkind device: initial experience.Catheter Cardiovasc Interv. 1999;46:
43-8.
9. Kalra GS, Verma PK, Dhall A, Singh S, Arora R. Transcatheter device closure of
ventricular septal defects: immediate results and intermediate-term follow-up. Am
Heart J. 1999;138:339-44.
10. Sideris EB, Walsh KP, Haddad JL, Chen CR, Ren SG, Kulkarni H. Occlusion of
congenital ventricular septal defects by the buttoned device. ‘‘Buttoned Device’’
Clinical Trials International Register. Heart. 1997;77:276-9.
11. Amin Z, Gu X, Berry JM, Titus JL, Gidding SS, Rocchini AP. Perventricular
closure of ventricular septal defects without cardiopulmonary bypass. Ann Thorac
Surg. 1999;68:149-53.
12. Amin Z, Danford DA, Lof J, Duncan KF, Froemming S. Intraoperative device
closure of perimembranous ventricular septal defects without cardiopulmonary
bypass: preliminary results with the perventricular technique. J Thorac Cardio-
vasc Surg. 2004;127:234-41.rgery c March 2009
Quansheng et al Congenital Heart Disease13. Amin Z, Woo R, Danford DA, Froemming SE, Reddy VM, Lof J, et al. Robotically
assisted perventricular closure of perimembranous ventricular septal defects: pre-
liminary results in Yucatan pigs. J Thorac Cardiovasc Surg. 2006;131:427-32.
14. Bacha EA, Cao QL, Starr JP, Waight D, Ebeid MR, Hijazi ZM. Perventricular
device closure of muscular ventricular septal defects on the beating heart: tech-
nique and results. J Thorac Cardiovasc Surg. 2003;126:1718-23.The Journal of Thoracic and15. Duan SH, Xing QS, Rong YB, Cao Q, Hou KF. Application of transthoracic
minimally invasive techniques in device closure of atrial septal defect without
cardiopulmonary bypass. Int J Cardiovasc Dis. 2005;32:305-6.
16. Pan SL, Xing QS, Rong YB, Cao Q, Wang KL, Liu XQ. Application of real-time
three-dimensional echocardiography in hybrid treatment of atrial septal defect.
Chin J Ultrasound. 2007;23:543-5.Cardiovascular Surgery c Volume 137, Number 3 559
C
H
D
